2022年2月11日

对制药行业的新技术进步感到好奇?探索我们对1268家全球初创公司的分析，了解他们的药理学解决方案如何影响您的业务!在1268家全球初创公司热图中，突出了5家顶级药物解决方案。这一数据驱动分析的见解来自大数据和人工智能(AI)驱动的StartUs insights发现平台，涵盖全球2 093 000多家初创公司和扩展公司。该平台为您提供了在特定领域的新兴技术和相关创业公司的详尽概述，只需几次点击。下面的全球初创公司热图揭示了我们为本研究分析的1268家模范初创公司和规模扩展公司的分布。此外，它还重点介绍了我们根据成立年份、地点、融资情况等标准精心挑选的五家制药初创公司。在这份报告中，您将探索这五家初创公司的解决方案。有关其他1263个药理学解决方案的见解，请与我们联系。总部位于英国的初创公司Antiverse使用机器学习优化药物发现过程。这家初创公司的解决方案使用深度测序和计算技术来选择原本会被遗漏的DNA序列。 These sequences are clustered based on their binding score that is assigned according to the similarity of sequence behavior, providing a greater understanding of the disease. Antiverse’s method thus allows access to multiple drug formulations while requiring less time in comparison to traditional methods. Dalriada enables Small Molecule Discovery Founding Year: 2017 Partner with Dalriada for Accelerated Drug Discovery Canadian startup Dalriada advances small molecule drug discovery. It specializes in Target-to-IND stage drug discovery projects on small molecule development. The startup facilitates drug development in immuno-oncology, inflammation and immunology, cardiovascular and metabolic diseases, neuroscience, and anti-infectives. This approach minimizes turn-around times, allows full customization of R&D, and improves partner engagement. Epiodyne enhances Receptor Pharmacology Use this solution for Analgesic Development Epiodyne is a US-based startup that develops novel analgesics capable of treating neurobehavioral symptoms for brain disorders. The startup’s treatment modulates endorphin signaling and relieves the debilitating symptoms of serious brain disorders. Epiodyne’s technology also aids the determination of high-resolution structures of multiple opioid receptors. This optimizes the activity level of receptor types and mitigates the family and societal impacts of serious mental illness and neurodegenerative diseases. Apnimed develops Sleep Apnea Cure Founding Year: 2017 Partner with Apnimed for Sleep Disorder Treatment US-based pharma startup Apnimed makes oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders. The startup’s proprietary approach studies the key underlying neurobiological mechanisms and designs therapies that target the irregularities that lead to airway obstruction. The startup’s drug candidate, AD109, targets two neurochemical pathways that control the upper airway musculature during sleep. The medicine’s dual mechanism of action leads to upper airway dilation and improved respiration and oxygenation during sleep. This approach substantially improves the treatment of patients with symptomatic snoring. FOx Biosystems facilitates Therapeutic Drug Monitoring Founding Year: 2016 Use this solution for Biomolecular Interaction Analysis FOx Biosystems is a Belgian startup that develops a proprietary technology that uses the surface plasmon resonance (SPR) principle for biomolecular interaction analysis. The startup’s eponymous solution offers an accurate, fast, and convenient alternative to techniques currently used for therapeutic drug monitoring. Its biosensors accurately detect, quantify and measure the potency of the antibody of interest in a variety of sample matrices. This enables researchers to generate high-quality, cost-effective biomolecular data accurately and over a wide range of applications. Discover more Pharma Startups Pharma startups such as the examples highlighted in this report focus on proteomics, drug development, bioinformatics as well as deep learning, AI, and machine learning. While all of these technologies play a major role in advancing the pharma industry, they only represent the tip of the iceberg. To explore pharma technologies in more detail, simply let us look into your areas of interest. For a more general overview, download our free Pharma Innovation Report to save your time and improve strategic decision-making. Get your free Pharma Innovation Report We’ll deliver it straight to your inbox! First & Last Name*